A Cross-Sectional Investigation for Verification of Globalization of Falsified Medicines in Cambodia, Indicated by Tablets of Sildenafil Citrate
Author:
Yoshida ,Yuasa ,Sovannarith ,Dararth ,Keila ,Kiet ,Tsuboi ,Tanimoto ,Kimura
Abstract
Medicine falsification is a global issue. Viagra, an erectile dysfunction therapeutic (EDT) medicine consisting primarily of sildenafil citrate, is the most commonly falsified medicine worldwide. Recently falsified EDTs have been reported multiple times in developing countries. The globalization of falsified EDTs has become a concern. In the present study, we selected sildenafil citrate tablets as an indicator and examined samples from a developing country, Cambodia, to investigate the availability of falsified sildenafil tablets in Cambodia and verify the current globalization status of falsified medicines from the standpoint of a developing country. Six samples of the originator Viagra, and 68 samples of generic sildenafil products were purchased from private drug outlets and wholesalers in Phnom Penh, Svay Rieng, and Battambang. The samples’ manufacturers were contacted to authenticate the samples. The quantities and dissolution rates of active ingredients were measured by a high-performance liquid chromatography system with photodiode array. Five generic samples were strongly suspected to be falsified medicines because of their extremely low quality; however, there was little distribution and no falsified medicine alleged to be produced by the originator of Viagra, which charges high prices. That finding indicates that falsification reflects local economic circumstances.
Funder
Japan Society for the Promotion of Science
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Reference27 articles.
1. World Health Organization: Substandard and Falsified Medical Products. Updated 31 January 2018http://www.who.int/mediacentre/factsheets/fs275/en/
2. Pharmaceutical Security Institute: Counterfeit Situation, Incident Trendshttp://psi-inc.org/incidentTrends.cfm
3. World Health Organization: WHO Global Surveillance and Monitoring Systemhttp://www.who.int/medicines/regulation/ssffc/surveillance/en/
4. Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献